title: Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer.
abstract: OBJECTIVE
  To determine the incidence and magnitude of the rapid increase in the serum PSA (riPSA) level after high-intensity focused ultrasound (HIFU) therapy for prostate cancer, and its correlation with clinical factors.
  
  
  METHODS
  A total of 176 patients with localized prostate cancer underwent HIFU therapy. Serum riPSA was determined on the basis of the same criteria as those for "PSA bounce", ie, an increase of ≥0.2 ng/ml with a spontaneous return to the prebounce level or lower. Patients were stratified according to neoadjuvant PSA level, T stage, risk group, age, Gleason score, pretreatment PSA level, post-treatment PSA nadir, and number of HIFU sessions.
  
  
  RESULTS
  riPSA was seen in 53% of patients during a median follow-up period of 43 months. A PSA nadir was achieved within 3 months for 85.1% of the treatments. In all cases, onset of riPSA was seen two days after HIFU therapy, and the median magnitude was 23.69 ng/ml. A magnitude of >2 ng/ml was seen in 89.4% of cases. Univariate analysis revealed that patients with riPSA were associated with usage of hormonal therapy and the post-treatment PSA nadir level. Multivariate Cox regression analysis revealed that riPSA and the number of HIFU sessions were predictors of biochemical recurrence. A significant statistical association was found between the presence of riPSA and the risk of biochemical failure only in the low- and intermediate-risk group.
  
  
  CONCLUSIONS
  Patients treated with HIFU who experience post-treatment riPSA may have an increased risk of biochemical recurrence, especially in non-high-risk patients.
authors: Department of Urology, Osaka Medical College, Osaka, Japan.
authors: Teruo
authors: T
authors: Inamoto
authors: Kazumasa
authors: K
authors: Komura
authors: Toshikazu
authors: T
authors: Watsuji
authors: Haruhito
authors: H
authors: Azuma
references: Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):698-702
references: 12377320
references: Urology. 2005 Aug;66(2):327-31
references: 16040084
references: Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53
references: 12738319
references: Urology. 2009 Dec;74(6):1183-90
references: 19428077
references: Radiother Oncol. 2008 Jul;88(1):102-7
references: 18453022
references: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1355-9
references: 16406391
references: Eur Urol. 2010 Oct;58(4):559-66
references: 20619958
references: Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1431-7
references: 17544597
references: J Androl. 2008 Sep-Oct;29(5):534-9
references: 18567642
references: Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):426-33
references: 17869662